Olema Pharmaceuticals (OLMA) shares are trading after first quarter results showed a net loss of US$53.09 million, with management emphasizing higher clinical spending, upcoming Phase 3 palazestrant data, and preparations for a possible commercial launch.

At a share price of US$13.82, Olema has seen its short term share price return fall 15.21% over the past month and 45.33% year to date, even as the 1 year total shareholder return is very large. This suggests that recent weakness has followed a strong earlier rerating as investors reassess the balance between trial progress, higher clinical spend and the potential for a future commercial launch.

If you are looking beyond a single biotech story and want to see what else is moving in related areas, it could be worth scanning 34 healthcare AI stocks

With Olema now valued at about US$1.19b and trading well below the average analyst price target, yet carrying no current revenue and a widening loss, investors have to ask: is this a genuine opportunity, or is the market already pricing in future growth?

DCF valuation points to a wide gap

Our DCF model estimates Olema's future cash flow value at about $185.42 per share, compared with the recent share price of $13.82. That is a very large gap, and it immediately raises questions about how much future cash generation is being built into that estimate.

The SWS DCF model works by projecting a stream of future cash flows for the business and then discounting those back to today using a required rate of return. For a clinical stage biotech like Olema, those cash flows are purely theoretical at this point, because the company currently reports no revenue and a net loss of $185.15 million.

In that context, a fair value estimate that sits far above the current share price reflects assumptions about the long run revenue potential of palazestrant and the rest of the pipeline, as well as the time it could take to reach any commercial scale. The model is highly sensitive to those inputs, so even relatively small changes in the growth path or profitability profile can move the fair value output considerably.

Result: DCF Fair value of $185.42 (UNDERVALUED)

However, the story also hinges on binary clinical outcomes and ongoing losses of US$185.15 million, so disappointing trial data or funding pressures could quickly reset expectations.

Another lens on valuation

While the SWS DCF model suggests Olema is trading well below an estimated fair value of $185.42, the P/B ratio tells a cooler story. At about 2.5x book value, the stock sits slightly above the US biotechs average of 2.4x, which points to less obvious mispricing on this measure and raises a simple question: which signal do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Olema Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of opportunity and concern feels hard to balance, treat it as a prompt to look at the full picture and decide where you stand. You can start with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Olema has caught your attention, do not stop here. Broaden your watchlist with a few focused stock ideas that many investors overlook.

• Target growth potential in overlooked corners of the market by scanning screener containing 22 high quality undiscovered gems that combine quality fundamentals with room to gain wider attention.
• Focus on resilience first and hunt through 67 resilient stocks with low risk scores to find stocks with characteristics that may suit a steadier, more defence minded approach.
• Prioritise financial strength and use solid balance sheet and fundamentals stocks screener (45 results) to zero in on companies where robust balance sheets support their long term business plans.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.